Moderna’s mRNA vaccine combined with Merck’s immunotherapy Keytruda succeeded in a late-stage trial for skin cancer, the companies said, sending shares of the vaccine maker up 60% in premarket ​trading. https://t.co/AbE55DcOOj https://t.co/qP9KEh1ECg ...